Fig. 3: Personalized MPC screening using patient-derived tumor organoids from transurethral resection of bladder tumors.
From: Microbial Product Cocktails for Personalized Cancer Immunotherapy
A, B Schematic of the personalized workflow for bladder cancer management and the procedure for preparing patient-derived tumor organoids for the iCARE assay. Panel b was hand-drawn by the authors using Procreate and finalized in PowerPoint; all elements are original. C-M Evaluation of 11 clinical samples (PPS1-11) using the iCARE assay. NK cell recruitment was assessed in response to MPC1-12 for PPS1-6 and an extended panel of MPCs for PPS7-11. PPS4 and PPS9 are recurrent tumors; PPS4 had undergone prior BCG treatment. N Heatmap showing upregulated chemokines in PPS2 relative to PPS1 and PPS3. O Heatmap illustrating chemokine modulation by MPC12, MPC9, and MPC5, with expression levels normalized to the untreated control. Genes with expression levels near the detection limit were excluded from the analysis. Data are presented as mean ± SE. P values were derived by the Welch T test followed by Dunn’s test, ns P > 0.05; * P < 0.05. n = 3, independent biological replicate experiments for PPS1-6; n = 5, independent biological replicate experiments for PPS7-8; n = 4, independent biological replicate experiments for PPS9; and n = 6, independent biological replicate experiments for PPS10-11. Source data are provided as a Source Data file.
